An immunocompetent 5 year-old girl presented with pyrexia of unknown origin associated with headache. Initial investigations showed leukocytosis and an increased erythrocyte sedimentation rate. A Widal-Weil Felix test, blood film for malarial parasites, mycoplasma IgM antibody, cultures from blood and urine, full blood picture, Mantoux test, and chest x-ray were all negative. A lumbar puncture was done as part of a work-up for pyrexia of unknown origin. Cryptococcus neoformans was seen on India ink examination and confirmed on culture. She was treated with 10 weeks of intravenous amphotericin B and 8 weeks of fluconazole. Further immunological tests did not reveal any defect in the cell-mediated immune system. C. neoformans meningitis may present with non-specific symptoms and should be considered in a work-up for pyrexia of unknown origin.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Fever of unknown origin.
BMJ
January 2025
Department of Internal Medicine, Radboud University Medical Center, Nijmegen, the Netherlands.
Hemophagocytic Lymphohistiocytosis in a Kidney Transplant Recipient: Case Report.
Transplant Proc
January 2025
Nephrology, Hospital Universitario Donostia, San Sebastián, España.
Hemophagocytic lymphohistiocytosis is a potentially fatal multisystemic inflammatory syndrome that is better understood in the pediatric population. Consequently, the diagnostic criteria for adults still derives from studies conducted in the pediatric population. Several genetic mutations and secondary causes, including infections, autoimmunity, and malignancy, have been reported as significant actors in this condition, especially in adults.
View Article and Find Full Text PDFClinical features, treatment, and prognosis of pembrolizumab -induced Stevens-Johnson syndrome / toxic epidermal necrolysis.
Invest New Drugs
January 2025
College of Pharmacy, Changsha Medical University, No. 1501 Leifeng Avenue, Xiangjiang New District, Changsha, Hunan, 410219, China.
The understanding of pembrolizumab-induced Stevens-Johnson syndrome (SJS) /toxic epidermal necrolysis (TEN) primarily derives from case reports, leaving specific clinical features largely unknown. This study aims to investigate the clinical characteristics associated with pembrolizumab-induced SJS/TEN and to encourage the judicious use of pembrolizumab. Retrieve reports on pembrolizumab induced SJS/TEN before September 30, 2024 for retrospective analysis.
View Article and Find Full Text PDF[Clinical Characteristics and Risk Factors of Infection in Hospitalized Patients with Multiple Myeloma with New Generation Therapies].
Zhongguo Shi Yan Xue Ye Xue Za Zhi
December 2024
The Third Hospital of Shanxi Medical University, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital,Taiyuan 030000, Shanxi Province, China.
Article Synopsis
- The study aimed to assess infection risks and characteristics in multiple myeloma patients receiving new therapies, involving 155 patients from a hospital over 5 years.
- The analysis identified 242 infection episodes, predominantly clinically defined infections, with lower respiratory tract being the most affected area.
- Key risk factors for developing infections included having advanced disease (ISS stage III), receiving multiple lines of treatment, and being frail.
In vitro to clinical efficacy: Neutralizing antibodies against severe acute respiratory syndrome coronavirus 2 strains.
J Infect Chemother
December 2024
Department of Infectious Diseases, Hiroshima University Hospital, 1-2-3 Kasumi, Minamiku, Hiroshima 734-8551, Japan. Electronic address:
Introduction: Neutralizing antibodies have been approved for coronavirus disease 2019 (COVID-19) treatment; however, no study has clarified the link among their neutralizing effect in vitro, the period of infectious virus shedding, and symptoms in the acute phase. Here, we aimed to assess the duration of virus shed and fever in patients with mild COVID-19 stratified by their characteristics and type of neutralizing antibody administered.
Methods: We evaluated the efficacy of neutralizing antibodies in terms of the duration of infectious virus excretion and fever in three groups: patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Delta strain treated with REGEN-CoV2 (REGN-CoV2 group) and patients infected with Omicron strain treated with S309 (S309 group) or untreated (untreated group).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!